Global Rare hematology disorders Market

Rare hematology disorders Comprehensive Study by Type (Rare blood cancers, Platelet based disorders, Plasma disorders, Myeloproliferative disorders, Genetic hematology disorders), Route of Administration (Oral Dosage Forms, Injectable Dosage Forms), Treatment Type (Plasma Derived Factors, Recombinant Factors, Others), Patients (Adult, Pediatric) Players and Region - Global Market Outlook to 2029

Rare hematology disorders Market by XX Submarkets | Forecast Years 2024-2029  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Rare blood diseases include red blood cell disease, beta-thalassemia, follicular lymphoma, myeloma, antiphospholipid syndrome, thrombotic thrombocytopenic purpura, and others. Around fifteen million individuals across the world suffer from thalassemic disorders and nearly 1.5% of the planet's population is calculable to be a carrier of β-thalassemia. The other hemoglobinopathies also are on the increase because of the increasing immigration of carriers from underdeveloped nations to developed regions of the globe. Rare blood disorders are tough to diagnose and treat. Government organizations and pharmaceutical corporations handling hematological disorders are focusing on research and development within the medical specialty space to new, effective, and advanced treatment for diseases and their complications. The growing prevalence of assorted blood diseases like anemia, myeloma, leukemia, and sickle cell anemia has diode hematologists to focus on numerous detection processes. As demand for relatively conducting relatively short diagnosing method is turning into the necessity of the hour, hematologists are looking for better treatment processes through the correct diagnosing process. The growing need to find numerous blood conditions has further propelled hematologists to focus on enhancing their diagnostic skills. In order to develop productive treatment techniques, medical specialists are considerably specialized in early diagnosing of the various hematologist diseases. Sure to these factors, the expansion of the world hematologist disease treatment market can still gain momentum during the forecast period.This growth is primarily driven by Growing Incidences of Blood Disorders .

AttributesDetails
Study Period2019-2029
Base Year2023
Forecast Period2023-2029
Volume UnitN
Value UnitUSD (Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


The Diseases & Therapeutic Areas sector in the region has been increasing at a sustainable rate and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as Shire (United States), Biogen (United States), Novo Nordisk A/S (Denmark), Bayer AG (Germany), CSL Behring (United States), Pfizer Inc. (United States), PRA Health Sciences (United States), Celgene Corporation (United States), Alexion (United States) and Amgen Inc. (United States), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:
In Dec. , 2023 Biogen Inc. announced that the European Commission has revoked the centralized marketing authorizations for generic versions of Biogen’s product TECFIDERA® (dimethyl fumarate) held by Accord, Mylan, Neuraxpharm, Polpharma and Teva.
In Nov. , 2023 Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced that a broad set of clinical and translational data from its programs will be presented at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition, to be held Dec. 9-12, 2023, in San Diego. The presentations will focus on rare blood disorders, including PK deficiency, thalassemia, sickle cell disease and anemia associated with lower-risk myelodysplastic syndromes (LR-MDS).The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.

Influencing Trend:
Increasing Precision Medicine Efforts in The Area of Hematology and Increasing Adoption of The Recombinant Factor

Market Growth Drivers:
Growing Incidences of Blood Disorders and The Rise in The Production of Recombinant Products

Challenges:
Limited Government Support for Conducting Extensive Research and Lack of Skilled Personnel

Restraints:
High Cost of Treatment Is Unaffordable

Opportunities:
Increasing Advancement in The Treatment Techniques

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mainly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the market's growth. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Data Sources of Rare hematology disorders Market Study

Primary Collection: InMail, LinkedIn Groups, Survey Monkey, Google, and Other professional Forums are some of the mediums utilized to gather primary data through key industry participants and appointees, subject-matter experts, C-level executives of Rare hematology disorders Industry, among others including independent industry consultants, experts, to obtain and verify critical qualitative commentary and opinion and quantitative statistics, to assess future market prospects.

The primary interviews and data collected as per the below protocols:
• By Designation: C-Level, D-Level, Others
• By Company Type: Tier 1, Tier 2, Tier 3

Secondary Data Sources such as Annual reports, Press releases, Analyst meetings, Conference calls, Investor presentations, Management statements, and SEC filings of Rare hematology disorders players along with Regulatory Sites, Association, World bank, etc were used as sources secondary set of data.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Rare hematology disorders Study Sheds Light on
— The Rare hematology disorders Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Rare hematology disorders industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Rare hematology disorders industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Rare blood cancers
  • Platelet based disorders
  • Plasma disorders
  • Myeloproliferative disorders
  • Genetic hematology disorders
By Route of Administration
  • Oral Dosage Forms
  • Injectable Dosage Forms

By Treatment Type
  • Plasma Derived Factors
  • Recombinant Factors
  • Others

By Patients
  • Adult
  • Pediatric

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Incidences of Blood Disorders
      • 3.2.2. The Rise in The Production of Recombinant Products
    • 3.3. Market Challenges
      • 3.3.1. Limited Government Support for Conducting Extensive Research
      • 3.3.2. Lack of Skilled Personnel
    • 3.4. Market Trends
      • 3.4.1. Increasing Precision Medicine Efforts in The Area of Hematology
      • 3.4.2. Increasing Adoption of The Recombinant Factor
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Rare hematology disorders, by Type, Route of Administration, Treatment Type, Patients and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Rare hematology disorders (Value)
      • 5.2.1. Global Rare hematology disorders by: Type (Value)
        • 5.2.1.1. Rare blood cancers
        • 5.2.1.2. Platelet based disorders
        • 5.2.1.3. Plasma disorders
        • 5.2.1.4. Myeloproliferative disorders
        • 5.2.1.5. Genetic hematology disorders
      • 5.2.2. Global Rare hematology disorders by: Route of Administration (Value)
        • 5.2.2.1. Oral Dosage Forms
        • 5.2.2.2. Injectable Dosage Forms
      • 5.2.3. Global Rare hematology disorders by: Treatment Type (Value)
        • 5.2.3.1. Plasma Derived Factors
        • 5.2.3.2. Recombinant Factors
        • 5.2.3.3. Others
      • 5.2.4. Global Rare hematology disorders by: Patients (Value)
        • 5.2.4.1. Adult
        • 5.2.4.2. Pediatric
      • 5.2.5. Global Rare hematology disorders Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Rare hematology disorders (Price)
      • 5.3.1. Global Rare hematology disorders by: Type (Price)
  • 6. Rare hematology disorders: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Shire (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Biogen (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Novo Nordisk A/S (Denmark)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Bayer AG (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. CSL Behring (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Pfizer Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. PRA Health Sciences (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Celgene Corporation (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Alexion (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Amgen Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Rare hematology disorders Sale, by Type, Route of Administration, Treatment Type, Patients and Region (value and price ) (2024-2029)
    • 7.1. Introduction
    • 7.2. Global Rare hematology disorders (Value)
      • 7.2.1. Global Rare hematology disorders by: Type (Value)
        • 7.2.1.1. Rare blood cancers
        • 7.2.1.2. Platelet based disorders
        • 7.2.1.3. Plasma disorders
        • 7.2.1.4. Myeloproliferative disorders
        • 7.2.1.5. Genetic hematology disorders
      • 7.2.2. Global Rare hematology disorders by: Route of Administration (Value)
        • 7.2.2.1. Oral Dosage Forms
        • 7.2.2.2. Injectable Dosage Forms
      • 7.2.3. Global Rare hematology disorders by: Treatment Type (Value)
        • 7.2.3.1. Plasma Derived Factors
        • 7.2.3.2. Recombinant Factors
        • 7.2.3.3. Others
      • 7.2.4. Global Rare hematology disorders by: Patients (Value)
        • 7.2.4.1. Adult
        • 7.2.4.2. Pediatric
      • 7.2.5. Global Rare hematology disorders Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Rare hematology disorders (Price)
      • 7.3.1. Global Rare hematology disorders by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Rare hematology disorders: by Type(USD Million)
  • Table 2. Rare hematology disorders Rare blood cancers , by Region USD Million (2018-2023)
  • Table 3. Rare hematology disorders Platelet based disorders , by Region USD Million (2018-2023)
  • Table 4. Rare hematology disorders Plasma disorders , by Region USD Million (2018-2023)
  • Table 5. Rare hematology disorders Myeloproliferative disorders , by Region USD Million (2018-2023)
  • Table 6. Rare hematology disorders Genetic hematology disorders , by Region USD Million (2018-2023)
  • Table 7. Rare hematology disorders: by Route of Administration(USD Million)
  • Table 8. Rare hematology disorders Oral Dosage Forms , by Region USD Million (2018-2023)
  • Table 9. Rare hematology disorders Injectable Dosage Forms , by Region USD Million (2018-2023)
  • Table 10. Rare hematology disorders: by Treatment Type(USD Million)
  • Table 11. Rare hematology disorders Plasma Derived Factors , by Region USD Million (2018-2023)
  • Table 12. Rare hematology disorders Recombinant Factors , by Region USD Million (2018-2023)
  • Table 13. Rare hematology disorders Others , by Region USD Million (2018-2023)
  • Table 14. Rare hematology disorders: by Patients(USD Million)
  • Table 15. Rare hematology disorders Adult , by Region USD Million (2018-2023)
  • Table 16. Rare hematology disorders Pediatric , by Region USD Million (2018-2023)
  • Table 17. South America Rare hematology disorders, by Country USD Million (2018-2023)
  • Table 18. South America Rare hematology disorders, by Type USD Million (2018-2023)
  • Table 19. South America Rare hematology disorders, by Route of Administration USD Million (2018-2023)
  • Table 20. South America Rare hematology disorders, by Treatment Type USD Million (2018-2023)
  • Table 21. South America Rare hematology disorders, by Patients USD Million (2018-2023)
  • Table 22. Brazil Rare hematology disorders, by Type USD Million (2018-2023)
  • Table 23. Brazil Rare hematology disorders, by Route of Administration USD Million (2018-2023)
  • Table 24. Brazil Rare hematology disorders, by Treatment Type USD Million (2018-2023)
  • Table 25. Brazil Rare hematology disorders, by Patients USD Million (2018-2023)
  • Table 26. Argentina Rare hematology disorders, by Type USD Million (2018-2023)
  • Table 27. Argentina Rare hematology disorders, by Route of Administration USD Million (2018-2023)
  • Table 28. Argentina Rare hematology disorders, by Treatment Type USD Million (2018-2023)
  • Table 29. Argentina Rare hematology disorders, by Patients USD Million (2018-2023)
  • Table 30. Rest of South America Rare hematology disorders, by Type USD Million (2018-2023)
  • Table 31. Rest of South America Rare hematology disorders, by Route of Administration USD Million (2018-2023)
  • Table 32. Rest of South America Rare hematology disorders, by Treatment Type USD Million (2018-2023)
  • Table 33. Rest of South America Rare hematology disorders, by Patients USD Million (2018-2023)
  • Table 34. Asia Pacific Rare hematology disorders, by Country USD Million (2018-2023)
  • Table 35. Asia Pacific Rare hematology disorders, by Type USD Million (2018-2023)
  • Table 36. Asia Pacific Rare hematology disorders, by Route of Administration USD Million (2018-2023)
  • Table 37. Asia Pacific Rare hematology disorders, by Treatment Type USD Million (2018-2023)
  • Table 38. Asia Pacific Rare hematology disorders, by Patients USD Million (2018-2023)
  • Table 39. China Rare hematology disorders, by Type USD Million (2018-2023)
  • Table 40. China Rare hematology disorders, by Route of Administration USD Million (2018-2023)
  • Table 41. China Rare hematology disorders, by Treatment Type USD Million (2018-2023)
  • Table 42. China Rare hematology disorders, by Patients USD Million (2018-2023)
  • Table 43. Japan Rare hematology disorders, by Type USD Million (2018-2023)
  • Table 44. Japan Rare hematology disorders, by Route of Administration USD Million (2018-2023)
  • Table 45. Japan Rare hematology disorders, by Treatment Type USD Million (2018-2023)
  • Table 46. Japan Rare hematology disorders, by Patients USD Million (2018-2023)
  • Table 47. India Rare hematology disorders, by Type USD Million (2018-2023)
  • Table 48. India Rare hematology disorders, by Route of Administration USD Million (2018-2023)
  • Table 49. India Rare hematology disorders, by Treatment Type USD Million (2018-2023)
  • Table 50. India Rare hematology disorders, by Patients USD Million (2018-2023)
  • Table 51. South Korea Rare hematology disorders, by Type USD Million (2018-2023)
  • Table 52. South Korea Rare hematology disorders, by Route of Administration USD Million (2018-2023)
  • Table 53. South Korea Rare hematology disorders, by Treatment Type USD Million (2018-2023)
  • Table 54. South Korea Rare hematology disorders, by Patients USD Million (2018-2023)
  • Table 55. Taiwan Rare hematology disorders, by Type USD Million (2018-2023)
  • Table 56. Taiwan Rare hematology disorders, by Route of Administration USD Million (2018-2023)
  • Table 57. Taiwan Rare hematology disorders, by Treatment Type USD Million (2018-2023)
  • Table 58. Taiwan Rare hematology disorders, by Patients USD Million (2018-2023)
  • Table 59. Australia Rare hematology disorders, by Type USD Million (2018-2023)
  • Table 60. Australia Rare hematology disorders, by Route of Administration USD Million (2018-2023)
  • Table 61. Australia Rare hematology disorders, by Treatment Type USD Million (2018-2023)
  • Table 62. Australia Rare hematology disorders, by Patients USD Million (2018-2023)
  • Table 63. Rest of Asia-Pacific Rare hematology disorders, by Type USD Million (2018-2023)
  • Table 64. Rest of Asia-Pacific Rare hematology disorders, by Route of Administration USD Million (2018-2023)
  • Table 65. Rest of Asia-Pacific Rare hematology disorders, by Treatment Type USD Million (2018-2023)
  • Table 66. Rest of Asia-Pacific Rare hematology disorders, by Patients USD Million (2018-2023)
  • Table 67. Europe Rare hematology disorders, by Country USD Million (2018-2023)
  • Table 68. Europe Rare hematology disorders, by Type USD Million (2018-2023)
  • Table 69. Europe Rare hematology disorders, by Route of Administration USD Million (2018-2023)
  • Table 70. Europe Rare hematology disorders, by Treatment Type USD Million (2018-2023)
  • Table 71. Europe Rare hematology disorders, by Patients USD Million (2018-2023)
  • Table 72. Germany Rare hematology disorders, by Type USD Million (2018-2023)
  • Table 73. Germany Rare hematology disorders, by Route of Administration USD Million (2018-2023)
  • Table 74. Germany Rare hematology disorders, by Treatment Type USD Million (2018-2023)
  • Table 75. Germany Rare hematology disorders, by Patients USD Million (2018-2023)
  • Table 76. France Rare hematology disorders, by Type USD Million (2018-2023)
  • Table 77. France Rare hematology disorders, by Route of Administration USD Million (2018-2023)
  • Table 78. France Rare hematology disorders, by Treatment Type USD Million (2018-2023)
  • Table 79. France Rare hematology disorders, by Patients USD Million (2018-2023)
  • Table 80. Italy Rare hematology disorders, by Type USD Million (2018-2023)
  • Table 81. Italy Rare hematology disorders, by Route of Administration USD Million (2018-2023)
  • Table 82. Italy Rare hematology disorders, by Treatment Type USD Million (2018-2023)
  • Table 83. Italy Rare hematology disorders, by Patients USD Million (2018-2023)
  • Table 84. United Kingdom Rare hematology disorders, by Type USD Million (2018-2023)
  • Table 85. United Kingdom Rare hematology disorders, by Route of Administration USD Million (2018-2023)
  • Table 86. United Kingdom Rare hematology disorders, by Treatment Type USD Million (2018-2023)
  • Table 87. United Kingdom Rare hematology disorders, by Patients USD Million (2018-2023)
  • Table 88. Netherlands Rare hematology disorders, by Type USD Million (2018-2023)
  • Table 89. Netherlands Rare hematology disorders, by Route of Administration USD Million (2018-2023)
  • Table 90. Netherlands Rare hematology disorders, by Treatment Type USD Million (2018-2023)
  • Table 91. Netherlands Rare hematology disorders, by Patients USD Million (2018-2023)
  • Table 92. Rest of Europe Rare hematology disorders, by Type USD Million (2018-2023)
  • Table 93. Rest of Europe Rare hematology disorders, by Route of Administration USD Million (2018-2023)
  • Table 94. Rest of Europe Rare hematology disorders, by Treatment Type USD Million (2018-2023)
  • Table 95. Rest of Europe Rare hematology disorders, by Patients USD Million (2018-2023)
  • Table 96. MEA Rare hematology disorders, by Country USD Million (2018-2023)
  • Table 97. MEA Rare hematology disorders, by Type USD Million (2018-2023)
  • Table 98. MEA Rare hematology disorders, by Route of Administration USD Million (2018-2023)
  • Table 99. MEA Rare hematology disorders, by Treatment Type USD Million (2018-2023)
  • Table 100. MEA Rare hematology disorders, by Patients USD Million (2018-2023)
  • Table 101. Middle East Rare hematology disorders, by Type USD Million (2018-2023)
  • Table 102. Middle East Rare hematology disorders, by Route of Administration USD Million (2018-2023)
  • Table 103. Middle East Rare hematology disorders, by Treatment Type USD Million (2018-2023)
  • Table 104. Middle East Rare hematology disorders, by Patients USD Million (2018-2023)
  • Table 105. Africa Rare hematology disorders, by Type USD Million (2018-2023)
  • Table 106. Africa Rare hematology disorders, by Route of Administration USD Million (2018-2023)
  • Table 107. Africa Rare hematology disorders, by Treatment Type USD Million (2018-2023)
  • Table 108. Africa Rare hematology disorders, by Patients USD Million (2018-2023)
  • Table 109. North America Rare hematology disorders, by Country USD Million (2018-2023)
  • Table 110. North America Rare hematology disorders, by Type USD Million (2018-2023)
  • Table 111. North America Rare hematology disorders, by Route of Administration USD Million (2018-2023)
  • Table 112. North America Rare hematology disorders, by Treatment Type USD Million (2018-2023)
  • Table 113. North America Rare hematology disorders, by Patients USD Million (2018-2023)
  • Table 114. United States Rare hematology disorders, by Type USD Million (2018-2023)
  • Table 115. United States Rare hematology disorders, by Route of Administration USD Million (2018-2023)
  • Table 116. United States Rare hematology disorders, by Treatment Type USD Million (2018-2023)
  • Table 117. United States Rare hematology disorders, by Patients USD Million (2018-2023)
  • Table 118. Canada Rare hematology disorders, by Type USD Million (2018-2023)
  • Table 119. Canada Rare hematology disorders, by Route of Administration USD Million (2018-2023)
  • Table 120. Canada Rare hematology disorders, by Treatment Type USD Million (2018-2023)
  • Table 121. Canada Rare hematology disorders, by Patients USD Million (2018-2023)
  • Table 122. Mexico Rare hematology disorders, by Type USD Million (2018-2023)
  • Table 123. Mexico Rare hematology disorders, by Route of Administration USD Million (2018-2023)
  • Table 124. Mexico Rare hematology disorders, by Treatment Type USD Million (2018-2023)
  • Table 125. Mexico Rare hematology disorders, by Patients USD Million (2018-2023)
  • Table 126. Rare hematology disorders: by Type(USD/Units)
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Rare hematology disorders: by Type(USD Million)
  • Table 138. Rare hematology disorders Rare blood cancers , by Region USD Million (2024-2029)
  • Table 139. Rare hematology disorders Platelet based disorders , by Region USD Million (2024-2029)
  • Table 140. Rare hematology disorders Plasma disorders , by Region USD Million (2024-2029)
  • Table 141. Rare hematology disorders Myeloproliferative disorders , by Region USD Million (2024-2029)
  • Table 142. Rare hematology disorders Genetic hematology disorders , by Region USD Million (2024-2029)
  • Table 143. Rare hematology disorders: by Route of Administration(USD Million)
  • Table 144. Rare hematology disorders Oral Dosage Forms , by Region USD Million (2024-2029)
  • Table 145. Rare hematology disorders Injectable Dosage Forms , by Region USD Million (2024-2029)
  • Table 146. Rare hematology disorders: by Treatment Type(USD Million)
  • Table 147. Rare hematology disorders Plasma Derived Factors , by Region USD Million (2024-2029)
  • Table 148. Rare hematology disorders Recombinant Factors , by Region USD Million (2024-2029)
  • Table 149. Rare hematology disorders Others , by Region USD Million (2024-2029)
  • Table 150. Rare hematology disorders: by Patients(USD Million)
  • Table 151. Rare hematology disorders Adult , by Region USD Million (2024-2029)
  • Table 152. Rare hematology disorders Pediatric , by Region USD Million (2024-2029)
  • Table 153. South America Rare hematology disorders, by Country USD Million (2024-2029)
  • Table 154. South America Rare hematology disorders, by Type USD Million (2024-2029)
  • Table 155. South America Rare hematology disorders, by Route of Administration USD Million (2024-2029)
  • Table 156. South America Rare hematology disorders, by Treatment Type USD Million (2024-2029)
  • Table 157. South America Rare hematology disorders, by Patients USD Million (2024-2029)
  • Table 158. Brazil Rare hematology disorders, by Type USD Million (2024-2029)
  • Table 159. Brazil Rare hematology disorders, by Route of Administration USD Million (2024-2029)
  • Table 160. Brazil Rare hematology disorders, by Treatment Type USD Million (2024-2029)
  • Table 161. Brazil Rare hematology disorders, by Patients USD Million (2024-2029)
  • Table 162. Argentina Rare hematology disorders, by Type USD Million (2024-2029)
  • Table 163. Argentina Rare hematology disorders, by Route of Administration USD Million (2024-2029)
  • Table 164. Argentina Rare hematology disorders, by Treatment Type USD Million (2024-2029)
  • Table 165. Argentina Rare hematology disorders, by Patients USD Million (2024-2029)
  • Table 166. Rest of South America Rare hematology disorders, by Type USD Million (2024-2029)
  • Table 167. Rest of South America Rare hematology disorders, by Route of Administration USD Million (2024-2029)
  • Table 168. Rest of South America Rare hematology disorders, by Treatment Type USD Million (2024-2029)
  • Table 169. Rest of South America Rare hematology disorders, by Patients USD Million (2024-2029)
  • Table 170. Asia Pacific Rare hematology disorders, by Country USD Million (2024-2029)
  • Table 171. Asia Pacific Rare hematology disorders, by Type USD Million (2024-2029)
  • Table 172. Asia Pacific Rare hematology disorders, by Route of Administration USD Million (2024-2029)
  • Table 173. Asia Pacific Rare hematology disorders, by Treatment Type USD Million (2024-2029)
  • Table 174. Asia Pacific Rare hematology disorders, by Patients USD Million (2024-2029)
  • Table 175. China Rare hematology disorders, by Type USD Million (2024-2029)
  • Table 176. China Rare hematology disorders, by Route of Administration USD Million (2024-2029)
  • Table 177. China Rare hematology disorders, by Treatment Type USD Million (2024-2029)
  • Table 178. China Rare hematology disorders, by Patients USD Million (2024-2029)
  • Table 179. Japan Rare hematology disorders, by Type USD Million (2024-2029)
  • Table 180. Japan Rare hematology disorders, by Route of Administration USD Million (2024-2029)
  • Table 181. Japan Rare hematology disorders, by Treatment Type USD Million (2024-2029)
  • Table 182. Japan Rare hematology disorders, by Patients USD Million (2024-2029)
  • Table 183. India Rare hematology disorders, by Type USD Million (2024-2029)
  • Table 184. India Rare hematology disorders, by Route of Administration USD Million (2024-2029)
  • Table 185. India Rare hematology disorders, by Treatment Type USD Million (2024-2029)
  • Table 186. India Rare hematology disorders, by Patients USD Million (2024-2029)
  • Table 187. South Korea Rare hematology disorders, by Type USD Million (2024-2029)
  • Table 188. South Korea Rare hematology disorders, by Route of Administration USD Million (2024-2029)
  • Table 189. South Korea Rare hematology disorders, by Treatment Type USD Million (2024-2029)
  • Table 190. South Korea Rare hematology disorders, by Patients USD Million (2024-2029)
  • Table 191. Taiwan Rare hematology disorders, by Type USD Million (2024-2029)
  • Table 192. Taiwan Rare hematology disorders, by Route of Administration USD Million (2024-2029)
  • Table 193. Taiwan Rare hematology disorders, by Treatment Type USD Million (2024-2029)
  • Table 194. Taiwan Rare hematology disorders, by Patients USD Million (2024-2029)
  • Table 195. Australia Rare hematology disorders, by Type USD Million (2024-2029)
  • Table 196. Australia Rare hematology disorders, by Route of Administration USD Million (2024-2029)
  • Table 197. Australia Rare hematology disorders, by Treatment Type USD Million (2024-2029)
  • Table 198. Australia Rare hematology disorders, by Patients USD Million (2024-2029)
  • Table 199. Rest of Asia-Pacific Rare hematology disorders, by Type USD Million (2024-2029)
  • Table 200. Rest of Asia-Pacific Rare hematology disorders, by Route of Administration USD Million (2024-2029)
  • Table 201. Rest of Asia-Pacific Rare hematology disorders, by Treatment Type USD Million (2024-2029)
  • Table 202. Rest of Asia-Pacific Rare hematology disorders, by Patients USD Million (2024-2029)
  • Table 203. Europe Rare hematology disorders, by Country USD Million (2024-2029)
  • Table 204. Europe Rare hematology disorders, by Type USD Million (2024-2029)
  • Table 205. Europe Rare hematology disorders, by Route of Administration USD Million (2024-2029)
  • Table 206. Europe Rare hematology disorders, by Treatment Type USD Million (2024-2029)
  • Table 207. Europe Rare hematology disorders, by Patients USD Million (2024-2029)
  • Table 208. Germany Rare hematology disorders, by Type USD Million (2024-2029)
  • Table 209. Germany Rare hematology disorders, by Route of Administration USD Million (2024-2029)
  • Table 210. Germany Rare hematology disorders, by Treatment Type USD Million (2024-2029)
  • Table 211. Germany Rare hematology disorders, by Patients USD Million (2024-2029)
  • Table 212. France Rare hematology disorders, by Type USD Million (2024-2029)
  • Table 213. France Rare hematology disorders, by Route of Administration USD Million (2024-2029)
  • Table 214. France Rare hematology disorders, by Treatment Type USD Million (2024-2029)
  • Table 215. France Rare hematology disorders, by Patients USD Million (2024-2029)
  • Table 216. Italy Rare hematology disorders, by Type USD Million (2024-2029)
  • Table 217. Italy Rare hematology disorders, by Route of Administration USD Million (2024-2029)
  • Table 218. Italy Rare hematology disorders, by Treatment Type USD Million (2024-2029)
  • Table 219. Italy Rare hematology disorders, by Patients USD Million (2024-2029)
  • Table 220. United Kingdom Rare hematology disorders, by Type USD Million (2024-2029)
  • Table 221. United Kingdom Rare hematology disorders, by Route of Administration USD Million (2024-2029)
  • Table 222. United Kingdom Rare hematology disorders, by Treatment Type USD Million (2024-2029)
  • Table 223. United Kingdom Rare hematology disorders, by Patients USD Million (2024-2029)
  • Table 224. Netherlands Rare hematology disorders, by Type USD Million (2024-2029)
  • Table 225. Netherlands Rare hematology disorders, by Route of Administration USD Million (2024-2029)
  • Table 226. Netherlands Rare hematology disorders, by Treatment Type USD Million (2024-2029)
  • Table 227. Netherlands Rare hematology disorders, by Patients USD Million (2024-2029)
  • Table 228. Rest of Europe Rare hematology disorders, by Type USD Million (2024-2029)
  • Table 229. Rest of Europe Rare hematology disorders, by Route of Administration USD Million (2024-2029)
  • Table 230. Rest of Europe Rare hematology disorders, by Treatment Type USD Million (2024-2029)
  • Table 231. Rest of Europe Rare hematology disorders, by Patients USD Million (2024-2029)
  • Table 232. MEA Rare hematology disorders, by Country USD Million (2024-2029)
  • Table 233. MEA Rare hematology disorders, by Type USD Million (2024-2029)
  • Table 234. MEA Rare hematology disorders, by Route of Administration USD Million (2024-2029)
  • Table 235. MEA Rare hematology disorders, by Treatment Type USD Million (2024-2029)
  • Table 236. MEA Rare hematology disorders, by Patients USD Million (2024-2029)
  • Table 237. Middle East Rare hematology disorders, by Type USD Million (2024-2029)
  • Table 238. Middle East Rare hematology disorders, by Route of Administration USD Million (2024-2029)
  • Table 239. Middle East Rare hematology disorders, by Treatment Type USD Million (2024-2029)
  • Table 240. Middle East Rare hematology disorders, by Patients USD Million (2024-2029)
  • Table 241. Africa Rare hematology disorders, by Type USD Million (2024-2029)
  • Table 242. Africa Rare hematology disorders, by Route of Administration USD Million (2024-2029)
  • Table 243. Africa Rare hematology disorders, by Treatment Type USD Million (2024-2029)
  • Table 244. Africa Rare hematology disorders, by Patients USD Million (2024-2029)
  • Table 245. North America Rare hematology disorders, by Country USD Million (2024-2029)
  • Table 246. North America Rare hematology disorders, by Type USD Million (2024-2029)
  • Table 247. North America Rare hematology disorders, by Route of Administration USD Million (2024-2029)
  • Table 248. North America Rare hematology disorders, by Treatment Type USD Million (2024-2029)
  • Table 249. North America Rare hematology disorders, by Patients USD Million (2024-2029)
  • Table 250. United States Rare hematology disorders, by Type USD Million (2024-2029)
  • Table 251. United States Rare hematology disorders, by Route of Administration USD Million (2024-2029)
  • Table 252. United States Rare hematology disorders, by Treatment Type USD Million (2024-2029)
  • Table 253. United States Rare hematology disorders, by Patients USD Million (2024-2029)
  • Table 254. Canada Rare hematology disorders, by Type USD Million (2024-2029)
  • Table 255. Canada Rare hematology disorders, by Route of Administration USD Million (2024-2029)
  • Table 256. Canada Rare hematology disorders, by Treatment Type USD Million (2024-2029)
  • Table 257. Canada Rare hematology disorders, by Patients USD Million (2024-2029)
  • Table 258. Mexico Rare hematology disorders, by Type USD Million (2024-2029)
  • Table 259. Mexico Rare hematology disorders, by Route of Administration USD Million (2024-2029)
  • Table 260. Mexico Rare hematology disorders, by Treatment Type USD Million (2024-2029)
  • Table 261. Mexico Rare hematology disorders, by Patients USD Million (2024-2029)
  • Table 262. Rare hematology disorders: by Type(USD/Units)
  • Table 263. Research Programs/Design for This Report
  • Table 264. Key Data Information from Secondary Sources
  • Table 265. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Rare hematology disorders: by Type USD Million (2018-2023)
  • Figure 5. Global Rare hematology disorders: by Route of Administration USD Million (2018-2023)
  • Figure 6. Global Rare hematology disorders: by Treatment Type USD Million (2018-2023)
  • Figure 7. Global Rare hematology disorders: by Patients USD Million (2018-2023)
  • Figure 8. South America Rare hematology disorders Share (%), by Country
  • Figure 9. Asia Pacific Rare hematology disorders Share (%), by Country
  • Figure 10. Europe Rare hematology disorders Share (%), by Country
  • Figure 11. MEA Rare hematology disorders Share (%), by Country
  • Figure 12. North America Rare hematology disorders Share (%), by Country
  • Figure 13. Global Rare hematology disorders: by Type USD/Units (2018-2023)
  • Figure 14. Global Rare hematology disorders share by Players 2023 (%)
  • Figure 15. Global Rare hematology disorders share by Players (Top 3) 2023(%)
  • Figure 16. Global Rare hematology disorders share by Players (Top 5) 2023(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Shire (United States) Revenue, Net Income and Gross profit
  • Figure 19. Shire (United States) Revenue: by Geography 2023
  • Figure 20. Biogen (United States) Revenue, Net Income and Gross profit
  • Figure 21. Biogen (United States) Revenue: by Geography 2023
  • Figure 22. Novo Nordisk A/S (Denmark) Revenue, Net Income and Gross profit
  • Figure 23. Novo Nordisk A/S (Denmark) Revenue: by Geography 2023
  • Figure 24. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 25. Bayer AG (Germany) Revenue: by Geography 2023
  • Figure 26. CSL Behring (United States) Revenue, Net Income and Gross profit
  • Figure 27. CSL Behring (United States) Revenue: by Geography 2023
  • Figure 28. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 29. Pfizer Inc. (United States) Revenue: by Geography 2023
  • Figure 30. PRA Health Sciences (United States) Revenue, Net Income and Gross profit
  • Figure 31. PRA Health Sciences (United States) Revenue: by Geography 2023
  • Figure 32. Celgene Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 33. Celgene Corporation (United States) Revenue: by Geography 2023
  • Figure 34. Alexion (United States) Revenue, Net Income and Gross profit
  • Figure 35. Alexion (United States) Revenue: by Geography 2023
  • Figure 36. Amgen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 37. Amgen Inc. (United States) Revenue: by Geography 2023
  • Figure 38. Global Rare hematology disorders: by Type USD Million (2024-2029)
  • Figure 39. Global Rare hematology disorders: by Route of Administration USD Million (2024-2029)
  • Figure 40. Global Rare hematology disorders: by Treatment Type USD Million (2024-2029)
  • Figure 41. Global Rare hematology disorders: by Patients USD Million (2024-2029)
  • Figure 42. South America Rare hematology disorders Share (%), by Country
  • Figure 43. Asia Pacific Rare hematology disorders Share (%), by Country
  • Figure 44. Europe Rare hematology disorders Share (%), by Country
  • Figure 45. MEA Rare hematology disorders Share (%), by Country
  • Figure 46. North America Rare hematology disorders Share (%), by Country
  • Figure 47. Global Rare hematology disorders: by Type USD/Units (2024-2029)
List of companies from research coverage that are profiled in the study
  • Shire (United States)
  • Biogen (United States)
  • Novo Nordisk A/S (Denmark)
  • Bayer AG (Germany)
  • CSL Behring (United States)
  • Pfizer Inc. (United States)
  • PRA Health Sciences (United States)
  • Celgene Corporation (United States)
  • Alexion (United States)
  • Amgen Inc. (United States)
Additional players considered in the study are as follows:
Genzyme Corporation (United States)
Select User Access Type

Key Highlights of Report


Jan 2024 216 Pages 79 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Rare hematology disorders Market Quantitative research analysis
Global Rare hematology disorders Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Historical year: 2019-2023; Base year: 2023; Forecast period: 2023 to 2029
Companies that are profiled in Global Rare hematology disorders Market are Shire (United States), Biogen (United States), Novo Nordisk A/S (Denmark), Bayer AG (Germany), CSL Behring (United States), Pfizer Inc. (United States), PRA Health Sciences (United States), Celgene Corporation (United States), Alexion (United States) and Amgen Inc. (United States) etc.
AMA Research predicts that United States Players will contribute to the maximum growth of Global Rare hematology disorders market throughout the forecasted period.

Know More About Global Rare hematology disorders Market Report?

Have a Query? Click Here

Other Related Reports

Astigmatism Treatment Comprehensive Study by Type (Eyeglasses, Contact lens, Orthokeratology, Laser surgeries, LASIK(Laser- Assisted In situ Keratomileusis), LASEK(Laser- Assisted Subepithelial Kerat...
$ 3750
Cutaneous Squamous Cell Carcinoma Comprehensive Study by Application (Hospitals, Cancer Institutes, Ambulatory Surgical Centers, Others), Treatment (Surgical (Moh’s Micrographic Surgery (MMS) and Ele...
$ 3450
Diverticular Treatment Comprehensive Study by Type (Antibiotics Treatment, Symptomatic Treatment), Application (Diverticulosis, Diverticulitis), Indication (Symptomatic Uncomplicated Diverticular Dis...
$ 3750
Bone Infection Treatment Comprehensive Study by Type (Penicillin, Cephalosporin, Aminoglycosides, Tetracycline, Others), Route of Administration (Oral, Topical, Injectable), Distribution Channel (Hos...
$ 3450
Cell Lymphoma Treatment Comprehensive Study by Type (Oral, Injection), Types (Topical products, Systematic Products), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
$ 3500
Refractory Multiple Myeloma Treatment Comprehensive Study by Type (Immunomodulatory drugs (IMiDs) (Thalidomide (THAL), Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib), Cytotoxic agents, High-Dos...
$ 3750